Leadership Overview
Eisai has 4 executives leading key functions including strategy, operations, and regional management.
Driven by a commitment to patient well-being, Eisai advances pharmaceutical innovation to address unmet medical needs globally, focusing on neurology and oncology.
Driven by a commitment to patient well-being, Eisai advances pharmaceutical innovation to address unmet medical needs globally, focusing on neurology and oncology.
Leadership Roles at Eisai
Toshio Imai - President & Chief Executive Officer & Scientific Chief & Officer
Toshio Imai, the President & Chief Executive Officer & Scientific Chief & Officer at Eisai, directs the overarching corporate strategy and scientific research initiatives. This leadership position involves guiding the company's global pharmaceutical development pipeline, with a particular emphasis on treatments for Alzheimer's disease, dementia, epilepsy, and various cancers. Overseeing the integration of scientific discovery with commercialization, Toshio Imai ensures that Eisai's therapeutic innovations translate into tangible patient benefits. The role demands a deep understanding of complex biological mechanisms and market dynamics to drive the development of novel medicines. By championing cutting-edge research, the President & Chief Executive Officer & Scientific Chief & Officer spearheads efforts to tackle challenging diseases and improve global health outcomes. This executive's vision shapes Eisai's long-term trajectory in the competitive pharmaceutical landscape, focusing on delivering breakthrough therapies.
Shaji Procida - President & Chief Operating Officer
Shaji Procida, the President & Chief Operating Officer at Eisai, executes the company's operational framework and day-to-day business functions. This critical role involves optimizing internal processes, managing global supply chains for pharmaceutical products, and ensuring efficient production of medications like Aricept, Methycobal, and Fycompa. Overseeing manufacturing, quality control, and distribution networks, Shaji Procida drives operational excellence across Eisai's diverse portfolio, which includes treatments for pain, insomnia, and autoimmune diseases. The President & Chief Operating Officer ensures seamless integration of research findings into scalable manufacturing, supporting the company's mission to deliver vital medicines worldwide. By streamlining operations, this executive enhances Eisai's capacity to meet patient demand and maintain high standards of product integrity. Shaji Procida's leadership ensures the robust delivery of Eisai's therapeutic solutions to markets across the globe.
Cynthia Schwalm - President
Cynthia Schwalm, the President at Eisai, spearheads strategic initiatives and market expansion, particularly within key geographic regions. This leadership function involves driving the commercial success of Eisai's pharmaceutical offerings, including innovative treatments for thyroid cancer, renal cell carcinoma, and breast cancer. Overseeing sales, marketing, and business development efforts, Cynthia Schwalm ensures that Eisai's therapeutic agents reach patients effectively. The President collaborates closely with research and development teams to align market needs with scientific advancements, fostering growth in areas such as oncology and neurology. By cultivating strategic partnerships and expanding market access, Schwalm strengthens Eisai's global presence and impact. This executive's focus on market penetration and patient access is crucial for delivering Eisai's life-changing medications to those in need.
Michael De - President, Eisai Machinery (USA)
Michael De, the President, Eisai Machinery (USA) at Eisai, directs the specialized operations of the company's machinery division within the United States. This role focuses on the development, manufacturing, and distribution of advanced pharmaceutical machinery, supporting Eisai's broader production capabilities. Overseeing technological innovation and operational efficiency in this sector, Michael De ensures that Eisai Machinery provides state-of-the-art equipment for pharmaceutical production. The President, Eisai Machinery (USA) plays a key part in maintaining the high standards required for drug manufacturing equipment, contributing to Eisai's overall product quality and reliability. By driving advancements in machinery technology, De supports the company's mission to deliver essential medicines. This executive's leadership ensures the division's contribution to Eisai's global operational strength.
Explore Leadership Teams in Manufacturing
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Headquartered in North Chicago, Illinois, the company operates internationally and focuses on advancing treatments that improve patient outcomes and overall quality of life. AbbVies scientific and commercial efforts are concentrated in several core therapeutic areas, including immunology, oncology, neuroscience, eye care, and medical aesthetics, along with other specialty areas where significant unmet medical needs exist. Through these focus areas, the company works to create therapies that help patients manage chronic, serious, and often life-altering diseases.
Company Leadership XY
CL
NR
MS
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.
Company Leadership
CA
SH
ST
Alvogen, founded in 2009 headquartered in Morristown, New Jersey, operates as a pharmaceutical company. The Company develops, manufactures, and markets parallel imported and generic drugs. Alvogen Pharma US serves clients worldwide.
Company Leadership SP
NB
JJ
JL
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Frequently Asked Questions Regarding Eisai Top Executives and Leadership Team
